GSK692342 + AS01B

GSK692342 + AS01B is an investigational **combination vaccine** candidate developed by GSK consisting of the antigen GSK692342 (most likely Hepatitis B surface antigen based on code name conventions and GSK pipeline conventions) formulated with the proprietary **AS01B Adjuvant System**. AS01B is a liposome-based adjuvant containing two immunostimulants: 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and the saponin QS-21. AS01B enhances the vaccine's immunogenicity by activating innate immune responses that promote both antigen-presenting cell activation and induction of robust cellular (CD4+ T cell) and humoral (antibody) responses. Vaccines using AS01B, such as the licensed herpes zoster vaccine (Shingrix), have demonstrated high efficacy. GSK692342 + AS01B is under clinical evaluation; its primary presumed indication is **prevention of hepatitis B infection**[6][1].